A

Business profile & competitive position

Agilent Technologies, Inc. operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. The company provides application-focused solutions for life sciences, diagnostics and applied markets, including instruments, software, services and consumables for the entire laboratory workflow. Following a November 2024 reorganization, it reports through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. It sells primarily through a direct sales force, supplemented by distributors, resellers, manufacturers’ representatives and electronic commerce.

The margin and return data support the view that Agilent has built meaningful competitive strength. A net margin of 19.5% and an ROE of 20.5% indicate it keeps a healthy slice of each revenue dollar and earns a strong return on the capital deployed. Those figures are consistent with a research-tools model that pairs instrument placements with recurring consumables and service revenue, though they do not by themselves guarantee future pricing power. A beta of 1.24 also tells investors the stock has historically moved more than the broad market.

Financial posture

Agilent’s market capitalization is $45.9 billion and it trades at a P/E ratio of 31.9. Against that valuation, the 19.5% net margin and 20.5% ROE provide important profitability context: the multiple is elevated relative to the broader market, but it rests on a business that converts roughly one-fifth of revenue into net income and posts return on equity above 20%. The 1.24 beta means shareholders should expect larger-than-market swings on macro or sector news.

Technically, the stock is priced at $162.465, with an RSI of 69.6 and a 50-day EMA of $146.23. That puts the price about 11% above its 50-day exponential moving average, and the RSI is approaching the commonly watched 70 level, though momentum indicators alone do not predict turning points.

Strategic priorities & outlook

In its most recent 10-K, Agilent described the November 2024 reorganization that moved the company to three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The stated goal is to support a market-focused, customer-centric strategy.

The filing lists several near-term operational priorities: expanding the liquid chromatography application space with new columns, new services and ongoing instrument and software product enhancements; continuing to improve mass spectrometry portfolio capabilities around performance, sensitivity, precision, robustness, ease of use and onboard intelligence; and advancing software and service solutions to help customers operate a digitally connected smart lab using data analytics, artificial intelligence and robotics.

As of October 31, 2025, Agilent employed roughly 18,100 people worldwide, including about 6,300 in Life Sciences and Diagnostics Markets, 7,400 in Agilent CrossLab and 2,500 in Applied Markets. The company relies on centralized order fulfillment and supply-chain operations, plus a global infrastructure organization that provides shared services in finance, IT, legal, procurement, workplace and HR. Its primary R&D and manufacturing sites are located in California, Colorado, Delaware, Massachusetts, Texas and Vermont in the U.S., and in Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom.

Macro & geopolitical exposure

As a Medical - Diagnostics & Research business, Agilent is exposed to the regulatory and reimbursement frameworks that govern clinical testing and diagnostics. Agencies such as the FDA, EMA and comparable global bodies influence product approvals and quality standards, while hospital and laboratory budgets affect demand for instruments and consumables. Tariffs and trade policy can move both costs and demand for capital equipment that is manufactured and sold across borders. The long list of international sites also means currency translation matters—a stronger U.S. dollar can reduce the reported value of overseas revenue. Supply-chain disruptions for precision components, logistics constraints and intellectual-property rules are additional industry-level risks, and shifts in academic or government research funding can swing spending on life-sciences tools.

Recent developments

On 2026-09-21, Agilent launched TapeStationDx Systems for clinical next-generation sequencing (NGS) sample quality control, targeting the clinical diagnostics workflow (businesswire.com).

On 2026-09-17, a regulatory filing noted that Bank of America Corp DE made a new investment in Agilent Technologies (defenseworld.net). That reflects institutional-trustee buying activity, not a strategic announcement from the company itself.

On 2026-09-16, Agilant announced a cash dividend of 25.5 cents per share (businesswire.com); a corrected version of the same release was issued the same day. At the current price of $162.465, that quarterly payout annualizes to roughly $1.02 per share, implying a yield near 0.6%.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Agilent has beaten earnings estimates six times, an 86% beat rate, with an average earnings surprise of 3%. The average five-trading-day move after those reports is 2.44% to the upside. That positive average, however, hides an important nuance: even on beat quarters, the post-earnings drift has not reliably continued in the direction of the surprise.

The most recent quarterly examples illustrate the disconnect. On 2026-08-26, Agilent reported EPS of $1.62 versus the $1.49 estimate—an 8.7% beat—and the stock rose 1.68% the next day but then fell 2.38% over the following five sessions. On 2026-05-27, it reported $1.49 versus $1.41, a 5.7% beat, and the stock surged 16.87% the next day and 18.61% over the next five days. That May result was a clear outlier that lifted the average. On 2025-11-24, a 0.4% beat ($1.59 versus $1.58431) produced a 2.34% next-day gain but a 3.12% five-day decline. The miss on 2026-02-25—$1.36 versus $1.37, a 0.7% shortfall—led to a 3.01% next-day drop and a 3.35% five-day decline.

The key takeaway is that beats have been far more common than misses, but a beat does not mechanically produce a sustained post-report rally. The next report is scheduled for 2026-11-23 after the market close, with a consensus EPS estimate of $1.72.

For a fuller picture of how institutional analysts view Agilent ahead of the November 2026 report—covering model assumptions, segment trends and risk factors—review the complete institutional verdict and consensus estimates rather than relying on headline numbers alone.